close

Fundraisings and IPOs

Date: 2018-01-05

Type of information: IPO

Company: Advicenne (France)

Investors:

Amount: €27.8 million

Funding type: IPO

Planned used:

  • Proceeds from the IPO and the listing on the regulated market of Euronext in Paris will enable Advicenne to further progress its strategy; primarily for preparing the commercial launch of its lead product, ADV7103, in Europe for the treatment of distal renal tubular acidosis (dRTA), and to continue its clinical development in the United States in this indication.  Proceeds will also enable Advicenne to continue the clinical development of the second indication, cystinuria, in Europe and in the United States. The net proceeds of the fundraising will be more specifically used for:
  • • Conducting a pivotal phase II/III clinical trial with ADV7103 for dRTA in the United States –  approximately €9 million
  • • Conducting a pivotal phase II/III clinical trial with ADV7103 for cystinuria in Europe – approximately €4 million
  • • The development of its commercial organisation for ADV7103 in Europe through commercial subsidiaries – approximately €5 million
  • • Conducting a phase II/III clinical trial in cystinuria in the United States for the remaining part.

Others:

  • • On January 5, 2018, Advicenne announced the partial exercise of the over-allotment option by Gilbert Dupont  acting on behalf of Gilbert Dupont and NIBC at close to 72% in connection with its Initial Public Offering (IPO) on Euronext’s regulated market in Paris. The partially exercised over-allotment option enabled the issue of 59,648 additional new shares at the Offer Price of €14.03 for a total amount of € 836,861.44 As a result, the total number of shares issued by Advicenne during the IPO amounts to 1,984,096 shares, representing about € 27.8 million. Following the partially exercised over-allotment option, the share capital of Advicenne will amount to 1,612,468.80 euros divided into 8,062,344 shares allocated (to the best of the Company’s knowledge) as follows:

    Number of shares

    % of share capital

    and voting rights (1)

    Luc-André Granier*

    250,000

    3,10%

    Caroline Roussel-Maupetit

    146,885

    1,82%

    Ludovic Robin

    28,971

    0,36%

    Nathalie Lemarié

    1,069

    0,01%

    Total executive directors

    426,925

    5,30%

    Total employees/committee members/consultants

    44,519

    0,55%

    IXO Private Equity* (2)

    1,462,082

    18,13%

    Bpifrance Investissement*(3)

    2,249,568

    27,90%

    Cemag Invest*

    689,212

    Therapeutic area: Rare diseases - Genetic diseases - Pediatric diseases

    Is general: Yes